---
title: "Beta Bionics | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 32.01 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294252704.md"
datetime: "2026-07-29T20:06:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294252704.md)
  - [en](https://longbridge.com/en/news/294252704.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294252704.md)
generator: "portal-rs"
---

# Beta Bionics | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 32.01 M

Revenue: As of FY2026 Q2, the actual value is USD 32.01 M, beating the estimate of USD 31.46 M.

EPS: As of FY2026 Q2, the actual value is USD -0.53, beating the estimate of USD -0.594.

EBIT: As of FY2026 Q2, the actual value is USD -25.58 M.

### Second Quarter 2026 Financial Highlights

#### Net Sales

Beta Bionics, Inc. reported net sales of $32.0 million for the second quarter of 2026, marking a 38% increase compared to $23.2 million in the second quarter of 2025. Durable Medical Equipment (DME) channel net sales were $20.4 million, an increase of 9% from $18.6 million in the second quarter of 2025. Pharmacy Benefit Plan (PBP) channel net sales surged by 153% to $11.6 million, up from $4.6 million in the second quarter of 2025.

#### Gross Margin

Gross margin for the quarter was 59.0%, an increase of 524 basis points from 53.8% in the second quarter of 2025.

#### Operational Metrics

Loss from operations was - $25.6 million, representing negative 80% of sales, compared to - $19.9 million or negative 86% of sales in the second quarter of 2025. Net loss was - $23.4 million, or negative 73% of sales, which was comparable to - $16.9 million or negative 73% of sales in the second quarter of 2025. Adjusted EBITDA was - $17.7 million, or negative 55% of sales, compared to - $14.5 million or negative 63% of sales in the second quarter of 2025.

#### New Patient Starts

New patient starts increased by at least 10% but less than 20% sequentially compared to the first quarter of 2026. Of these, 69% originated from multiple daily injections (MDI), and a high 30s percentage were reimbursed through the PBP channel.

#### Cash and Investments

As of June 30, 2026, Beta Bionics, Inc. held $225.2 million in cash, cash equivalents, short and long-term investments.

### Six Months Ended June 30, 2026 Financial Highlights

#### Net Sales

For the six months ended June 30, 2026, total net sales were $59,639 thousand, compared to $40,877 thousand for the same period in 2025. DME channel net sales totaled $37,336 thousand, up from $32,471 thousand in 2025. PBP channel net sales reached $22,303 thousand, a significant increase from $8,406 thousand in 2025.

#### Gross Margin

Gross margin for the six-month period was 59.3%, an improvement from 52.5% in the prior year period.

#### Operational Metrics

Loss from operations for the six months was - $49,849 thousand, compared to - $38,514 thousand in 2025. Net loss was - $45,298 thousand, a slight improvement from - $45,525 thousand in 2025. Adjusted EBITDA was - $35,374 thousand, compared to - $30,061 thousand in 2025.

#### Cash Flow

The provided reference does not include a cash flow statement.

### 2026 Full Year Guidance

Beta Bionics, Inc. maintains its estimated total revenue forecast at $131 million to $136 million for the full year 2026. The company expects 37% to 39% of new patient starts to be reimbursed through the PBP channel, unchanged from previous guidance. The estimated gross margin for the full year has been updated to 58.5% to 59.5%, a slight adjustment from the previously stated 57.5% to 59.5%.

### Related Stocks

- [BBNX.US](https://longbridge.com/en/quote/BBNX.US.md)

## Related News & Research

- [Have Beta Bionics Insiders Been Selling Stock?](https://longbridge.com/en/news/298111067.md)
- [Beta Bionics CEO Sean Saint disposes of 5,641 common shares for $113,261.01](https://longbridge.com/en/news/298077212.md)
- [Beta Bionics (NASDAQ:BBNX) Insider Sells 4,221 Shares of Stock](https://longbridge.com/en/news/298030991.md)
- [Alexandria Real Estate Equities declares Q3 2026 dividend of R$ 0.63 per unit](https://longbridge.com/en/news/297928934.md)
- [Pininfarina announces availability of H1 2026 interim financial report](https://longbridge.com/en/news/298044460.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**